<DOC>
	<DOCNO>NCT01478698</DOCNO>
	<brief_summary>Hypothesis : Intraperitoneal tPA DNase well tolerate number different dos . Different dos tPA DNase dose-related effect inflammatory marker ( CRP intraperitoneal white cell count ) . Aims : 1 . To examine tolerability different dos intraperitoneal tPA DNase compare standard treatment . 2 . To examine change biochemical clinical outcome PD Peritonitis addition intraperitoneal tPA DNase usual therapy .</brief_summary>
	<brief_title>The Safety Tolerability Intra-abdominal t-PA DNase Peritonitis Peritoneal Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Peritonitis</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>1 . PD patient 2 . Proven peritonitis ( define least 2 : ( ) Symptoms and/or sign peritonitis ; ( ii ) Cloudy dialysate OR dialysate white cell count &gt; 100x 106/L &gt; 50 % neutrophil ; ( iii ) Positive culture dialysate 3 . Age &gt; 18 year old 1 . More one organism culture 2 . Contraindication systemic thrombolysis ( eg . current recent stroke , major haemorrhage major trauma ; proliferative retinopathy ; major surgery previous 5 day ) 3 . Known sensitivity DNase tPA 4 . Pregnancy lactate mother 5 . Expected survival le 3 month 6 . Clinical indication PD catheter removal , define treat team 7 . Inability provide write informed consent 8 . Systemic anticoagulation 9 . Severe uncontrolled hypertension 10 . Documented ulcerative gastrointestinal disease last three month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>peritoneal dialysis</keyword>
	<keyword>peritoneal dialysis , continuous ambulatory</keyword>
	<keyword>peritonitis</keyword>
</DOC>